OpenURL Connection Search

Select item for more details and to access through your institution.

Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
Published in:
Open Forum Infectious Diseases, 2024, v. 11, n. 7, p. 1, doi. 10.1093/ofid/ofae365
By:
- Scholten, Stefan;
- Cahn, Pedro;
- Portilla, Joaquín;
- Bisshop, Fiona;
- Hodder, Sally;
- Ruane, Peter;
- Kaplan, Richard;
- Wynne, Brian R;
- Man, Choy Y;
- Grove, Richard;
- Wang, Ruolan;
- Jones, Bryn;
- Ait-Khaled, Mounir;
- Kisare, Michelle;
- Okoli, Chinyere
Publication type:
Article
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Published in:
Open Forum Infectious Diseases, 2023, v. 10, n. 3, p. 1, doi. 10.1093/ofid/ofad101
By:
- Rolle, Charlotte-Paige;
- Berhe, Mezgebe;
- Singh, Tulika;
- Ortiz, Roberto;
- Wurapa, Anson;
- Ramgopal, Moti;
- Jayaweera, Dushyantha T;
- Leone, Peter A;
- Matthews, Jessica E;
- Cupo, Michael;
- Underwood, Mark R;
- Angelis, Konstantinos;
- Wynne, Brian R;
- Merrill, Deanna;
- Nguyen, Christopher;
- Wyk, Jean van;
- Zolopa, Andrew R
Publication type:
Article
Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants.
Published in:
Pharmacology Research & Perspectives, 2023, v. 11, n. 6, p. 1, doi. 10.1002/prp2.1151
By:
- Zhang, Ying;
- Bush, Mark;
- Yazdani, Parto;
- Zhan, Joyce;
- Wen, Bo;
- Bainbridge, Veronica;
- Wynne, Brian R.;
- Joshi, Samit;
- Lataillade, Max
Publication type:
Article
Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults.
Published in:
Clinical Pharmacology in Drug Development, 2017, v. 6, n. 6, p. 577, doi. 10.1002/cpdd.332
By:
- Buchanan, Ann M.;
- Holton, Michael;
- Conn, Ian;
- Davies, Mark;
- Choukour, Mike;
- Wynne, Brian R.
Publication type:
Article
Efficacy and Safety of Switching to Dolutegravir/ Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis.
Published in:
Infection & Chemotherapy, 2022, v. 54, p. 271
By:
- Scholten, Stefan;
- Cahn, Pedro;
- Ruane, Peter;
- Kaplan, Richard;
- Portilla, Joaquín;
- Hodder, Sally;
- Bisshop, Fiona;
- Wynne, Brian R.;
- Grove, Richard;
- Bontempo, Gilda;
- Moodley, Riya;
- Jones, Bryn;
- Ait-Khaled, Mounir;
- Okoli, Chinyere;
- Gyo-Seung Gu
Publication type:
Article
High rates of virologic suppression with DTG/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load >500,000 c/mL: 48-week subgroup analysis of the STAT study.
Published in:
Infection & Chemotherapy, 2022, v. 54, p. S295
By:
- Rolle, Charlotte-Paige;
- Berhe, Mezgebe;
- Singh, Tulika;
- Ortiz, Roberto;
- Wurapa, Anson;
- Ramgopal, Moti;
- Jayaweera, Dushyantha T.;
- Leone, Peter A.;
- Matthews, Jessica E.;
- Cupo, Michael;
- Underwood, Mark R.;
- Angelis, Konstantinos;
- Wynne, Brian R.;
- Merrill, Deanna;
- Nguyen, Christopher;
- van Wyk, Jean;
- Sang-Kyu Shin;
- Zolopa, Andrew R.
Publication type:
Article

Found: 6

Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants.

Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults.

Efficacy and Safety of Switching to Dolutegravir/ Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis.

High rates of virologic suppression with DTG/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load >500,000 c/mL: 48-week subgroup analysis of the STAT study.